In a landmark achievement for tuberculosis (TB) research, a new Pan-African study has identified blood-based, sputum-independent biomarkers capable of predicting TB treatment failure and recurrence with remarkable accuracy. Published yesterday in the prestigious Communications Medicine journal, part of the Nature portfolio, the research draws from the Pan-African TB Sequel project and highlights significant contributions from South African scientists at the University of the Witwatersrand (Wits) in Johannesburg.
This breakthrough addresses a critical gap in TB management, where traditional sputum tests often fail due to low bacterial loads, especially in HIV-co-infected patients or those with extrapulmonary disease. By focusing on host immune responses in blood, these biomarkers offer a non-invasive, reliable alternative to monitor treatment outcomes and prevent relapse, potentially transforming care in high-burden regions like South Africa.
🔬 The Burden of TB in South Africa and Africa
Tuberculosis remains South Africa's leading cause of death from an infectious disease, with approximately 249,000 new cases reported in 2024 alone, including 14,000 drug-resistant forms. The country grapples with intertwined epidemics of TB and HIV, where co-infection exacerbates recurrence risks and mortality—claiming 56,000 lives in 2023 despite declining incidence. Globally, Africa has made strides, reducing TB incidence by 28% and deaths by 46% from 2015 to 2024, surpassing some WHO End TB Strategy milestones, yet challenges persist amid funding squeezes.
In South Africa, the National TB Recovery Plan 4.0 (2025–2026) emphasizes innovative diagnostics and treatment monitoring to curb recurrence, which affects up to 10–15% of cured patients, often due to reinfection in high-transmission settings. HIV-positive individuals face even higher odds, with studies showing microbial translocation and immune dysregulation driving relapse. This new research positions Wits researchers at the forefront of solutions tailored to these realities.
For aspiring researchers eyeing TB studies, opportunities abound at institutions like Wits through higher-ed research jobs focused on infectious diseases.
Unpacking the Pan-African TB Sequel Study
The study stems from the TB Sequel project, a multi-country initiative funded by Germany's BMBF, tracking 1,430 pulmonary TB patients across South Africa, Tanzania, Mozambique, and The Gambia since 2017. Its goal: understand long-term sequelae, pathogenesis, and risk factors post-treatment, with follow-up extending to 10 years.
In Johannesburg, Wits' Clinical HIV Research Unit at Helen Joseph Hospital, alongside the Aurum Institute, recruited participants, contributing vital data from high HIV-prevalence urban settings. Key South African contributors include Mohammed Rassool and Salome Charalambous from Wits' Faculty of Health Sciences and School of Public Health.
This matched case-control analysis involved 40 cases (recurrent TB or treatment failure) and 37 controls, perfectly balanced by age, sex, HIV status, and site. Cases were subcategorized into non-converters (persistent positive sputum), reverters (positive at treatment end), and post-treatment recurrences.
Methods: How the Biomarkers Were Identified
Researchers analyzed peripheral blood at baseline and months 2, 4, 6, 9, 12 post-treatment. Two biomarker classes were evaluated:
- T-cell Activation Markers (TAM-TB): Flow cytometry on stimulated peripheral blood mononuclear cells (PBMCs) measured Mycobacterium tuberculosis (MTB)-specific CD4+ T-cell expression of CD38, CD27, HLA-DR, and Ki67 after stimulation with MTB peptides.
- Transcriptomic Signatures: RNA sequencing from whole blood assessed established gene sets: Sweeney3 (3 genes), RISK6 (6 genes), and MAMS6 (6 genes), known for TB diagnosis and risk prediction.
Sputum was the gold standard via microscopy, culture (MGIT/ LJ media), and MPT64 confirmation. Statistical rigor included ROC curves for performance (AUC, sensitivity, specificity).
This blood-centric approach bypasses sputum challenges, making it ideal for children, HIV patients, and remote clinics—contexts prevalent in South African townships.
Explore research assistant jobs at Wits or similar unis for hands-on experience in such protocols.
Key Findings: Superior Performance of CD38 and Gene Signatures
The standout performer was CD38 expression on MTB-specific IFNγ+ CD4 T-cells, detecting recurrence at months 9/12 with 100% sensitivity (95% CI: 56.6–100%), 78% specificity (95% CI: 56.5–99.4%), and AUC 0.98 (95% CI: 0.91–1.00). It flagged non-converters early during treatment.
| Biomarker | Sensitivity (95% CI) | Specificity (95% CI) | AUC (95% CI) |
|---|---|---|---|
| CD38 (TAM-TB) | 100% (56.6–100%) | 78% (56.5–99.4%) | 0.98 (0.91–1.00) |
| MAMS6 | 75% (50–100%) | 93% (0–100%) | 0.78 (0.56–1) |
| RISK6 | 75% (50–100%) | 87% (0–93%) | 0.81 (0.60–1) |
| Sweeney3 | 75% (50–100%) | 87% (0–100%) | 0.83 (0.66–1) |
Transcriptomic signatures matched well for recurrence (AUC 0.78–0.83) but underperformed for end-of-treatment reversion. Cases showed persistently elevated markers, unlike controls where levels normalized.
These results held across HIV statuses and sites, underscoring Pan-African applicability.
Implications for TB Treatment and Public Health in South Africa
Current TB regimens (6 months standard) succeed in 85%, but failures drive resistance and transmission. These biomarkers enable risk-stratified care: extend therapy for high-risk patients, prioritize preventive therapy, or switch regimens early—potentially averting thousands of recurrences yearly in SA.Read the full study
In HIV hotspots like Johannesburg, where 35% of study cases were co-infected, blood tests could integrate with ART clinics, reducing mortality. Economically, averting one recurrence saves ~R50,000 in costs per patient.
For clinicians and researchers, this paves the way for point-of-care tests. Wits' role exemplifies how South African higher ed drives global health innovations; check university jobs in Johannesburg for openings.
South African Higher Education's Role in Global TB Research
Wits, a top SA university, has long led TB efforts via its Health Sciences faculty and partnerships like Aurum Institute. Recent works include neutrophil biomarkers in sputum and plasma signatures for incipient TB. The TB Sequel collaboration boosts capacity-building, training African scientists in advanced immunology and genomics.
This publication elevates SA's research profile, attracting funding and talent. Postdocs and lecturers in infectious diseases are in demand—visit postdoc jobs or lecturer jobs.
Challenges and Future Directions
While promising, small sample sizes limit precision (wide CIs), and no Gambian/SA PBMCs affected TAM-TB analysis. Future trials must validate in larger cohorts, children, and MDR-TB.
- Develop rapid lateral-flow CD38 tests.
- Integrate with AI for transcriptomics.
- Scale via WHO prequalification for African rollout.
Horizon: Blood biomarkers could end sputum reliance, aligning with SA's TB Recovery Plan and global End TB goals by 2030.
Read related advice on thriving as a postdoc.
Stakeholder Perspectives and Real-World Impact
Lead author Bernadette Bauer (LMU Munich) emphasizes: "These markers reliably detect poor outcomes across Africa." Wits' Salome Charalambous highlights local relevance: urban HIV-TB dynamics demand such tools.
Patients stand to benefit most: fewer relapses mean better lives. Policymakers can leverage for NSP updates; funders like BMBF signal more Pan-African grants ahead.
Photo by Markus Winkler on Unsplash
Conclusion: A New Era for TB Control
This Nature publication cements Pan-African collaboration's power, with Wits shining bright. By predicting recurrence sans sputum, it promises shorter regimens, lower resistance, and saved lives in SA and beyond. Researchers, explore rate my professor for mentors, higher ed jobs, career advice, university jobs, or post a job to join the fight.
